Corvus Pharmaceuticals Inc logo

Corvus Pharmaceuticals Inc(CRVS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
3-STAR RATING
PASS
LAST CLOSE
$10.6
11/16/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CRVS

11/16/2026: CRVS (3-star) is currently NOT-A-BUY. Pass it for now.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel small-molecule immunotherapies, led by its primary asset, soquelitinib. The company's main strengths include an experienced leadership team, a differentiated pipeline targeting ITK across both oncology and immunology, and a solid cash runway extending into 2028. Its primary growth opportunity lies in expanding soquelitinib into high-prevalence inflammatory diseases such as atopic dermatitis and asthma. However, key risks include heavy cash burn, a lack of commercial product revenue, and the binary nature of clinical trial outcomes. The stock suits high-risk growth investors willing to monitor upcoming clinical data readouts and regulatory milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveThe company offers high-upside exposure to novel clinical-stage immunotherapy pipelines targeting large markets.
Momentum investorStrong fit while signal remains positiveStock price behavior is heavily influenced by near-term clinical trial data readouts and biotech sentiment cycles.
Value investorWeak fitThe absence of earnings, revenue, and commercial assets makes traditional valuation metrics inapplicable.
Dividend investorWeak fitThe company does not pay dividends and retains all cash to fund clinical research.
Low-risk investorWeak fitClinical-stage biotechnology stocks carry high binary risk tied to trial outcomes and regulatory decisions.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical trial updates and capital raises frequently trigger sharp stock price movements.
Valuation riskMedium / highPricing is entirely speculative based on future commercial potential rather than current cash flows.
Competition risk (clinical immunotherapy and targeted drugs)HighWell-funded competitors are developing alternate therapies targeting similar oncologic and immunologic pathways.
Business qualityMediumThe firm features experienced scientific leadership but lacks a diversified commercial product portfolio.
Dividend incomeLow / noneNo cash returns are distributed to shareholders.
Execution riskHighSuccess depends entirely on completing complex clinical trials and securing regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 897.52M USD
Price to earnings Ratio -
1Y Target Price 31.5
Price to earnings Ratio -
1Y Target Price 31.5
Volume (30-day avg) 1.1M shares
Beta 1.52
52 Weeks Range 6.39 - 26.95
Updated Date 11/15/2026
52 Weeks Range 6.39 - 26.95
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.72

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.7%
Active BUY / eligible
69 / 110
30-Day BUY Count Change
+30
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
46.3%
Active BUY / eligible
19 / 41
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 356.28%
Avg. Invested days 33
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/16/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CRVS receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
CRVS has solid overall fundamentals (4 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+75.5%) is partially offset by soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
CRVS's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is CRVS's strongest growth driver at +75.5% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (+0.0%, slightly negative) and free-cash-flow growth (-29.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 84.8% and approximately 86.6% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 3.97% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Orbimed Advisors LLC 8.50%
BlackRock Inc 8.47%
State Street Corp 5.31%
T. Rowe Price Associates, Inc. 4.49%
Vanguard Capital Management, LLC 3.91%

Unit Economics (Per $1K Revenue)

★★★★★
CRVS generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
CRVS has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Product Revenue / Commercial SalesCurrently zero commercial product sales as all pipeline assets remain investigational.The company does not yet generate product revenues and operates at a net loss.
Collaborations and GrantsPotential upfront fees, milestone payments, and research funding derived from strategic partnerships.Financial inflows outside of equity offerings rely heavily on partnership terms and licensing deals.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 695.20M
Price to Sales(TTM) -
Enterprise Value 695.20M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.36
Shares Outstanding 84.35M
Shares Floating 73.02M
Shares Outstanding 84.35M
Shares Floating 73.02M
Percent Insiders 3.97
Percent Institutions 84.79

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.